Jaweed Akhter, MD
Internal Medicine · Beaumont, TXNPI 1427002823
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.6%), speaking fees and education — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Lilly USA, LLC at 43.5% of the total. Reporting peaked in 2021 at $2,120 and has fallen 77.5% since, to $477 in 2025.
Across 190 payments — averaging $21.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Dexcom, Inc.$589
- Novo Nordisk$310
- Abbott$192
- AstraZeneca$180
- Sanofi-aventis U.S. LLC$137
- plus $953 from 20 others
What the payments were for
- Speaking & faculty fees$1,62539%
- Food & beverage$2,40658%
- Education$1453%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 15 | $1,816 |
| Dexcom, Inc. | 74 | $589 |
| Novo Nordisk | 15 | $310 |
| Abbott | 15 | $192 |
| AstraZeneca | 11 | $180 |
| Sanofi-aventis U.S. LLC | 8 | $137 |
| Bayer | 7 | $134 |
| Xeris Pharmaceuticals, Inc. | 7 | $126 |
| Mannkind Corporation | 4 | $121 |
| Corcept Therapeutics | 5 | $93 |
| Pfizer | 3 | $55 |
| Sequel Med Tech, LLC | 2 | $46 |
| BETA Bionics, Inc. | 4 | $45 |
| Amarin Pharma, Inc. | 3 | $45 |
| Merck | 3 | $42 |
| Medtronic(2 entities) | 3 | $41 |
| Insulet Corporation | 2 | $33 |
| Shire North American Group Inc | 1 | $25 |
| Cequr Corporation | 1 | $22 |
| Ascendis Pharma Endocrinology Inc | 1 | $21 |
| AbbVie | 1 | $20 |
| Nevro Corp. | 1 | $18 |
| Amgen | 1 | $18 |
| Madrigal Pharmaceuticals | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,176 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 812 | $1,319,006 |
| Tresiba Flextouch U-200Insulin Degludec | 726 | $884,757 |
| FarxigaDapagliflozin Propanediol | 253 | $270,723 |
| JardianceEmpagliflozin | 217 | $237,483 |
| TrulicityDulaglutide | 107 | $188,200 |
| MounjaroTirzepatide | 97 | $154,172 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 96 | $142,577 |
| Novolog FlexpenInsulin Aspart | 412 | $112,550 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 114 | $88,945 |
| Tresiba Flextouch U-100Insulin Degludec | 149 | $88,181 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 73 | $57,755 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 89 | $55,755 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 22 | $49,393 |
| Humalog Kwikpen U-100Insulin Lispro | 101 | $45,073 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 20 | $33,928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $310 | $1,355,901863 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,816 | $342,372204 claims |
| AstraZenecaFarxiga | $180 | $270,723253 claims |
| Boehringer IngelheimJardiance | $15 | $237,483217 claims |
| MerckJanuvia | $42 | $19,80219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Beaumont
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.